Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Alì Taher, Natalia Holot et al.|The Lancet Haematology|2025Cited by 17
Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE StudySujit Sheth, Maria Domenica Cappellini, Olivier Hermine et al.|Blood|2022Cited by 8
Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND StudyKhaled M. Musallam, Kevin H.M. Kuo, Alì Taher et al.|Blood|2023Cited by 6
Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover StudyMaria Domenica Cappellini, Sujit Sheth, Vip Viprakasit et al.|Blood|2023Cited by 1
Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup AnalysisKevin H.M. Kuo, Vip Viprakasit, Pranee Sutcharitchan et al.|Blood|2023Cited by 1